Evaluation of Antithrombin Deficiency in Patients of Intensive Care Unit Placed on Extracorporeal Membrane Oxygenation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04133844

Acronym

ATECMO

Enrollment

Registered

2019-10-21

Start date

2020-05-05

Completion date

2021-05-18

Last updated

2021-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Cardiac Insufficiency

Keywords

extracorporeal membrane oxygenation

Brief summary

Prospective, monocentric, non-interventional study in patients placed on extracorporeal membrane oxygenation (ECMO)

Detailed description

Our hypothesis is that ECMO initiation is responsible for a severe decrease of antithrombin level in a high proportion of patients who develop heparin resistance.

Interventions

BIOLOGICALBlood sample

Blood sample collection from a peripheral catheter at ECMO initiation (H0), then 2h, 6h, 12h, 24h and daily from day 2 to day 7 or at ECMO discontinuation

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Any ICU patient of receiving veno-arterial extracorporeal membrane oxygenation * Patients who have not expressed opposition to participate

Exclusion criteria

* Arterial thrombosis or progressive venous thrombosis * Contraindication to heparin * Constitutional deficiency in antithrombin * Patient refusal * Minor patient * Protected major (safeguard justice, trusteeship and guardianship) and persons deprived of liberty

Design outcomes

Primary

Measure	Time frame	Description
To study antithrombin level from during the first 24h after ECMO initiation	Day 7	Blood sample at ECMO initiation (H0), then 2h, 6h, 12h, 24h and daily from day 2 to day 7 or at ECMO discontinuation

Secondary

Measure	Time frame	Description
To study the prevalence of antithrombin (AT) deficiency (≤70%) at each time point (from H0 to day 7)	Day 7	Blood sample
To study relationship between antithrombin level and heparin resistance	Day 7	Blood sample
To study antithrombin level 24h after initialization of ECMO	Hour 24	Blood sample at 24h
To study clinical factors associated with AT deficiency	Day 7	Blood sample
To describe clinical evolution of patients according to initial AT level	Hour 0	Blood sample
To study relationship between antithrombin level and thrombin generation test	Day 7	Blood sample

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026